Abstract 188P
Background
Survival and prognosis data in cholangiocarcinoma patients in routine clinical practice has been limited. This study aimed to determine the survival of cholangiocarcinoma patients and to investigate prognostic factors for survival in cholangiocarcinoma patients.
Methods
This cohort study retrospectively reviewed 158 records of cholangiocarcinoma patients treated in Oncology Unit, Department of Medicine, Rajavithi hospital from 1 January 2004 to 31 December 2017. Clinical characteristics, treatments, and outcomes were collected and analyzed.
Results
There were 158 patients whose median age was 58 years old while 69.6% of those had a good performance status (ECOG PS) of 0-1. The median survival time for all was 9.5 months (95% CI = 7.3-11.6) and the 1-year survival rate was 37.3%. After curative surgery (n = 49), 35 patients (71.4%) had tumor recurrence with the median disease-free survival of 8.81 months (95% CI = 6.93-10.68). Patients who received first-line palliative chemotherapy (n = 68) had the median progression-free survival of 4.3 months (95% CI = 3.51-5.10). The overall response rate to first-line chemotherapy was 7.3%. Variables analyzed by univariate analysis including ECOG PS of 3-4 (p < 0.001), neutrophil/lymphocyte ratio >/= 4 (p 0.004), intrahepatic cholangiocarcinoma (compared with hilar cholangiocarcinoma, p 0.005), distant metastasis in all sites (p < 0.001) and TNM stage IV disease (p < 0.001) were significant factors for shorter survival time. While surgical treatment, adjuvant chemotherapy and radiation, and palliative chemotherapy were significantly associated with better survival (p < 0.001). Multivariate analysis identified ECOG PS of 3-4 (p 0.001), intrahepatic type (p 0.001) and TNM stage IV disease (p 0.033) as independent poor prognostic factors for survival. Furthermore, receiving surgery and palliative chemotherapy administration (p < 0.001) were independent significant predictors associated with better survival compared to best supportive care alone.
Conclusions
Poor ECOG performance status of 3, intrahepatic cholangiocarcinoma type and TNM stage IV disease were adverse prognostic factors whereas surgical treatment and palliative chemotherapy had a crucial role in treatment for cholangiocarcinoma patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Oncology unit, Internal Medicine Department, Rajavithi Hospital.
Funding
Rajavithi Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
41P - Clinical verification on the relationship between serum lipid metabolism and the immune microenvironment in breast cancer patients
Presenter: Wataru Goto
Session: Poster display session
Resources:
Abstract
42P - Genome wide copy number analysis of circulating tumour cells in breast cancer liver metastasis
Presenter: Saber Imani
Session: Poster display session
Resources:
Abstract
43P - A hotspot variants p.H1047R and p.H1047L in p110α/ΔNp63α complex affects structure, function and contributes to susceptibility metastatic breast cancer
Presenter: Zou Linglin
Session: Poster display session
Resources:
Abstract
44P - Correlation of circulating tumour cells with PET-CT in metastatic breast cancer
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract
45P - The challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumour location
Presenter: Hubert Beaumont
Session: Poster display session
Resources:
Abstract
46P - Plasma soluble CD36 of breast cancer based on pathological and clinical characteristics
Presenter: Aditia Romadhoni
Session: Poster display session
Resources:
Abstract
47P - Investigation of the use of a novel S-1 administration method for treating metastatic and recurrent breast cancer
Presenter: MAYUKO MIKI
Session: Poster display session
Resources:
Abstract
48P - Development of MDA-MB-231-3D-Spheroid as a reliable model for studying Nav1.5 and nNav1.5-mediated breast cancer metastasis
Presenter: Ahmad Murtadha
Session: Poster display session
Resources:
Abstract
49P - Biochemical study on modifying role of variants of leptin gene and its receptor on serum leptin levels in breast cancer
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
50P - Prognostic factors of recurrence or distant metastasis in elderly breast cancer patients
Presenter: Seungju Lee
Session: Poster display session
Resources:
Abstract